Vertex reported a rebound in sales for Casgevy, the gene‑edited therapy developed with CRISPR Therapeutics, with quarterly sales more than tripling versus the prior quarter. Management cited the therapy as a bright spot in the company’s financials and a contributor to commercial momentum. Casgevy is a CRISPR‑based, ex vivo gene‑editing product authorized for a rare genetic indication; rising uptake highlights commercial viability for gene‑edited medicines and signals strengthening demand as manufacturing and distribution scale. Analysts view the growth as validation for gene‑editing commercialization strategies.